Concurrent Session 8: Clinical Outcomes

Date: Saturday 30 September 2017
Time: 09.00-10.30
Room: Mozart Hall 1-3

Chairs: Hervé Bachelez, Marjan Garmyn

Concurrent talks are 8 minutes plus 2 minutes discussion.



067 (Poster 011)
Pediatric cancers in neurofibromatosis type 1
S Peltonen,1 R Matti,2 R Kallionpää,3 J Pitkäniemi2 and J Peltonen3 1 Dept. of Dermatol., Univ. of Turku and Turku Univ. Hosp., Turku, Finland, 2 Finnish Cancer Registry, Helsinki, Finland and 3 Instit. of Biomedicine, Univ. of Turku, Turku, Finland

09.10-09.20 068 (Poster 203)
Preliminary therapeutic target validation of the IL-36 receptor in psoriasis

SK Mahil,1 M Peakman,1 R Trembath,1 J Wright,2 J Barker1 and F Capon1 1 King’s College London, London, United Kingdom and 1 Bradford Royal Infirmary, Bradford, United Kingdom
09.20-09.30 069 (Poster 023)
Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome
D Giusti,1,2 G Gatouillat,1,2 S Le Jan,1 J Plée,1,3 P Bernard,1,3 FD Antonicelli1 and B Pham1,2 1 Dermatology, University of Reims Champagne-Ardenne, Reims, France, 2 Immunology, Reims University Hospital, Reims, France and 3 Dermatology, Reims University Hospital, Reims, France
09.30-09.40 070 (Poster 019)
Distinct clinicopathologic and radiological manifestations of the skin, lung, and muscle diseases in patients with dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies

H Fukamatsu,1 Y Hirai,1 T Kaji,1 S Morizane,1 E Yokoyama,1 T Hamada,1 T Oono2 and K Iwatsuki1 1 Dermatology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan and 2 Dermatology, Okayama Red-Cross Hospital, Kita-ku Okayama, Japan
09.40-09.50 071 (Poster 007)
Sustained Response Following Withdrawal of Guselkumab Treatment Correlates With Reduced Th17 and Th22 Effector Cytokine Levels

P Branigan, X Liu, Y Chen, B Scott, Z Yao, S Li, Y Wasfi, M Song, K Campbell and E Muñoz-Elías Janssen Research & Development, LLC, Spring House, USA
09.50-10.00 072 (Poster 002)
Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis

CE Griffiths,1 K Reich,2 D Thaçi,3 S Gerdes,3 P Arenberger,4 K Kingo,5 J Weglowska6 and H Woehling7 1 University of Manchester, Manchester, United Kingdom, 2 Dermatologikum Hamburg, SCIderm GmbH, Hamburg, Germany, 3 University Hospital Schleswig-Holstein, Lübeck and Kiel, Germany, 4 Charles University, Prague, Czech Republic, 5 Tartu University Hospital, Tartu, Estonia, 6 Szpital Specjalistyczny we Wroclawiu, Wroclaw, Poland and 7 HEXAL AG/Sandoz, Holzkirchen, Germany
10.00-10.10 073 (Poster 004)
Patients with hidradenitis suppurativa have a high psychiatric disease burden: A Finnish nationwide registry study
L Huilaja,1 H Tiri,1 J Jokelainen,2 M Timonen2 and K Tasanen11 Department of Dermatology, University of Oulu, Oulu, Finland and 2 Center for Life Course Epidemiology and Systems Medicine, University of Oulu, Oulu, Finland
10.10-10.20 074 (Poster 527)
Safety dose and prediction of immune-related adverse event of nivolumab combined with IFN-beta in patients with advanced melanoma

T Fujimura, Y Kambayashi, S Furudate, T Hidaka, K Tanita, Y Sato and S Aiba Dermatology, Tohoku University, graduate school of medicine, Sendai, Japan